A recent retrospective study evaluated the visual and anatomical outcomes of patients treated with faricimab intravitreal injections (IVI) for neovascular age-related macular degeneration (nAMD). The study included 170 eyes, both previously treated and treatment-naïve.
Key Findings:
Visual Acuity (VA):
- Treatment-naïve eyes showed a greater improvement in best-corrected visual acuity (BCVA) after one (+5.00 letters) and three injections (+12.50 letters), though statistical significance was limited.
- Previously treated eyes experienced modest gains in BCVA (+0.59 to +1.57 letters).
- Eyes switching from aflibercept demonstrated a significant BCVA improvement (+2.15 letters after three injections).
Anatomical Improvements:
- Central subfield thickness (CST) reduced significantly in all groups, particularly in treatment-naïve eyes (-94.10 μm after one injection).
- Pigment epithelial detachment (PED) and retinal fluid metrics improved notably, especially in refractory cases.
Safety:
- Ocular adverse events were reported in three cases. One patient experienced two stroke events during treatment.
Faricimab shows promise in enhancing visual and anatomical outcomes in nAMD, particularly in treatment-refractory cases.
Reference
Kunzmann BC, Schweig AS, Bartz-Schmidt KU, et al. Real-World-Data of Treatment-Naïve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2024;18:4029-4039. doi: 10.2147/OPTH.S482948. PMID: 39749039; PMCID: PMC11694016.
Related Content
